Sensus Healthcare (NASDAQ:SRTS) Stock Price Crosses Below 50-Day Moving Average – Time to Sell?

Sensus Healthcare, Inc. (NASDAQ:SRTS) shares crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $6.85 and traded as low as $5.36. Sensus Healthcare shares last traded at $5.38, with a volume of 280,695 shares.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SRTS. Maxim Group lifted their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 15th. HC Wainwright raised their target price on Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. Finally, Lake Street Capital started coverage on Sensus Healthcare in a research note on Friday, January 31st. They issued a “buy” rating and a $18.00 target price for the company.

Sensus Healthcare Trading Down 3.2 %

The firm has a market capitalization of $88.18 million, a PE ratio of 13.45 and a beta of 1.24. The stock has a 50 day simple moving average of $6.79 and a 200 day simple moving average of $6.84.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. As a group, equities analysts anticipate that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current year.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its position in shares of Sensus Healthcare by 8.5% during the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after purchasing an additional 11,525 shares in the last quarter. XTX Topco Ltd boosted its position in shares of Sensus Healthcare by 76.0% during the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after purchasing an additional 13,619 shares in the last quarter. Truvestments Capital LLC bought a new stake in shares of Sensus Healthcare during the third quarter valued at approximately $32,000. Marshall Wace LLP boosted its position in shares of Sensus Healthcare by 99.6% during the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company’s stock valued at $915,000 after purchasing an additional 65,994 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Sensus Healthcare by 5.3% during the fourth quarter. Renaissance Technologies LLC now owns 430,934 shares of the company’s stock valued at $2,982,000 after purchasing an additional 21,600 shares in the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.